Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir

Antiviral Therapy

Volumn 18, Issue 5, 2013, Pages 709-715

  Benito, José M ^a   Sánchez Parra, Clara ^a   Maida, Ivana ^b   Aguilera, Antonio ^c   Rallón, Norma I ^a   Rick, Fernanda ^a   Labarga, Pablo ^a   Fernández Montero, José V ^a   Barreiro, Pablo ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSITY OF SASSARI   (Italy)

^c HOSPITAL DE CONXO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; EMTRICITABINE; INTERLEUKIN 28B; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; TELAPREVIR; TENOFOVIR; VIRUS RNA;

ADULT; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG USE; FEMALE; HEPATITIS C; HUMAN; INFECTION RATE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84883468671     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2614     Document Type: Article

References (37)

1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-1444.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-264.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
4. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
5. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-1024.
6. Poordad F, McCone J, Bacon B, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
7. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
8. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
9. Medrano J, Neukam K, Rallón N, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010;51:1209-1216.
10. Berg T, Sarrazin C, Hermann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-609.
11. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon a-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-960.
12. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
13. Andriulli A, Iacobellis A, Valvano MR, et al. Estimates of HCV-1 patients attaining RVR following dual therapy with peginterferon and ribavirin. Dig Dis Sci 2013;58:1371-1382.
14. Bouchardeau F, Cantaloube JF, Chevaliez S, et al. Improvement of HCV genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 2007;45:1140-1145.
15. Ziol M, Handra-Luca A, Kettaneh A, et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
16. Castera L. Transient elastography and other on invasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009;16:300-314.
17. Kirk GD, Astemborski J, Mehta SH, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009;48:963-972.
18. Poordad F, Bronowicki JP, Gordon S, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012;143:608-618.
19. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-129.
20. Rallón NI, Soriano V, Naggie S, et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C viruscoinfected patients treated with pegylated interferon and ribavirin. AIDS 2011;25:1025-1033.
21. Vispo E, Rallon NI, Labarga P, Barreiro P, Benito JM, Soriano V. Different impact of IL28B polymorphisms on response to peginterferon-a plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. J Clin Virol 2012;55:58-61.
22. Rallón NI, Pineda JA, Soriano V, et al. Differences in virological response to peginterferon-a plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b. J Acquir Immune Defic Syndr 2012;60:117-123.
23. Poveda E, Vispo E, Barreiro P, et al. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain. Antivir Ther 2012;17:571-575.
24. Grint D, Peters L, Vogel M, et al. Temporal changes and regional difference in treatment uptake of hepatitis C therapy in EuroSIDA. J Int AIDS Soc 2012;15 Suppl 4:18118.
25. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011;18:11-16.
26. Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-1713.
27. Barreiro P, Vispo E, Labarga P, Soriano V. Management and treatment of chronic hepatitis C in HIV patients. Semin Liver Dis 2012;32:138-146.
28. Núñez M, Miralles C, Berdún MA, et al. Role of weightbased ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007;23:972-982.
29. Soriano V, Sherman K, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIVHCV co-infected patients. AIDS 2011;25:2197-2208.
30. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut 2012;61 Suppl 1:i47-i58.
31. Ingiliz P, Rockstroh J. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int 2012;32:1194-1199.
32. Naggie S, Sulkowski M. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012;142:1324-1334.
33. Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin Infect Dis 2012;54:979-983.
34. Sulkowski M, Sherman K, Soriano V, et al. Telaprevir in combination with peginterferon-alfa 2a/ribavirin in HCVHIV coinfected patients: SVR24 final study results. 63rd American Association for the Study of Liver Diseases. 23-26 November 2012, Boston, MA, USA. Abstract 76.
35. Mallolas J, Pol S, Rivero A, et al. Boceprevir plus peginterferon/ ribavirin for the treatment of HCV/HIV co-infected patients: end of treatment (week 48) interim results. 47th European Association for the Study of the Liver. 18-22 April 2012, Barcelona, Spain. Abstract 50.
36. Bruno S, Mangia A. Futility of antiviral treatments for hepatitis C: an evolving concept entering the direct antiviral agents era. Dig Liver Dis 2013;45:356-361.
37. Seden K, Back D, Shoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010;65:1079-1085.